CD44 and CD44v6 are Correlated with Gastric Cancer Progression and Poor Patient Prognosis: Evidence from 42 Studies
CD44 and CD44v6 are Correlated with Gastric Cancer Progression and Poor Patient Prognosis: Evidence from 42 Studies
复制标题
DOI：
10.1159/000452570
复制
发表时间：
2016-01-01
影响因子：
--
通讯作者：
Huang, Lingsha
中科院分区：
文献类型：
--
作者：
Fang, Min;Wu, Junrong;Huang, Lingsha
背景/目的：胃癌（GC）患者总CD 44及其亚型CD 44 v6水平的预后能力仍存在争议。因此，我们的研究旨在总结这两种蛋白在胃癌的临床病理和预后意义。方法：检索PubMed文献。Web of Science和Embase数据库用于识别合格研究。使用比值比（OR）和95%置信区间（CI）评估效果。结果：共有42项研究（包括6，229例患者）纳入本分析。21篇文献中提到总CD 44，结果显示CD 44与T分类、N分类、远处转移、淋巴管浸润及TNM分期呈正相关。CD 44过表达患者的5年总生存率较低（OR = 3.35，95%CI = 1.83-6.13）。24项研究中提到了CD 44 v6，结果与总CD 44相似。然而，总CD 44或CD 44 v6表达与肿瘤大小和组织学分级无关。结论：胃癌组织中CD 44、CD 44 v6的高表达与胃癌的进展及预后有关。CD 44和CD 44 v6可能是诊断或预后胃癌的有用生物标志物。(C)2016作者（s）由S. Karger AG，巴塞尔。
Background/Aims: The prognostic power of the levels of total CD44 and its isoform CD44v6 for patients with gastric cancer (GC) remains controversial. Therefore, our study aims to generalize the clinicopathological and prognostic significance of these two proteins in GC. Methods: A literature search of the PubMed. Web of Science and Embase databases was conducted to identify eligible studies. The odds ratio (OR) with a 95% confidence interval (CI) was used to assess the effects. Results: In all, 42 studies including 6,229 patients were included in this analysis. Total CD44 was mentioned in 21 papers, and the results showed that CD44 was positively correlated with the T category, the N category, distant metastasis, lymphatic invasion and TNM stage. Moreover, patients with CD44 overexpression had a lower 5-year overall survival (OS) rate (OR = 3.35, 95%CI = 1.83-6.13). CD44v6 was mentioned in 24 studies, with results that were similar to those for total CD44. However, total CD44 or CD44v6 expression was not correlated with tumor size and histological grade. Conclusion: High CD44 or CD44v6 expression levels were correlated with cancer progression and poor prognosis in patients with GC. Both CD44 and CD44v6 may be useful diagnostic or prognostic biomarkers for GC. (C) 2016 The Author(s) Published by S. Karger AG, Basel.